Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
暂无分享,去创建一个
Shang-Jyh Hwang | Ming‐Lung Yu | Jer-Ming Chang | M. Yeh | Chung‐Feng Huang | C. Dai | Po-Cheng Liang | M. Hsieh | Zu-Yau Lin | Jee-Fu Huang | W. Chuang | Jiun-Chi Huang | Y. Chiu | Jia-Jung Lee | Shinn-Cherng Chen | M. Hsieh | Tyng-Yuan Jang | Cheng-Ting Hsu | Po-Yao Hsu | Sheng-Wen Niu | Yu-Ju Wei | Szu‐Chia Chen | M. Yu | Yi‐Hung Lin | Ching‐I. Huang | Ching-I Huang | Jee‐Fu Huang | Chung-Feng Huang | Ming‐Yen Hsieh | Ming‐Lung Yu
[1] W. Lai,et al. Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication , 2020, The Kaohsiung journal of medical sciences.
[2] J. Kao,et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[3] J. Kao,et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[4] J. Kao,et al. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). , 2020, The American journal of gastroenterology.
[5] S. Markova,et al. Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis. , 2019, Journal of Hepatology.
[6] R. Morillo,et al. Prevalence of the potential drug–drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain , 2019, Gastroenterología y Hepatología (English Edition).
[7] M. Jadoul,et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. , 2019, Kidney international.
[8] Douglas E Schaubel,et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] J. Kao,et al. Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan , 2018, Alimentary pharmacology & therapeutics.
[10] Mei-Yi Wu,et al. Taiwan renal care system: A learning health‐care system , 2018, Nephrology.
[11] F. Fabrizi,et al. ‘Real-life’ experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease , 2018, The International journal of artificial organs.
[12] A. Bruchfeld,et al. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. , 2017, Journal of hepatology.
[13] G. Everson,et al. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions , 2017, World journal of gastroenterology.
[14] Gamal Esmat,et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.
[15] M. Jadoul,et al. Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[16] Ming‐Lung Yu,et al. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment , 2016, Clinical Cancer Research.
[17] S. Zyoud,et al. Use of complementary and alternative medicines in haemodialysis patients: a cross-sectional study from Palestine , 2016, BMC Complementary and Alternative Medicine.
[18] Y. Yazdanpanah,et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. , 2016, Journal of hepatology.
[19] M. Kumar,et al. APASL consensus statements and recommendation on treatment of hepatitis C , 2016, Hepatology International.
[20] M. Manns,et al. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] Ming‐Lung Yu,et al. Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C , 2015, Medicine.
[22] Ding‐Shinn Chen,et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial , 2014, Gut.
[23] Shang-Jyh Hwang,et al. Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics , 2014, Hepatology International.
[24] H. Kuo,et al. Discrepancy between Serological and Virological Analysis of Viral Hepatitis in Hemodialysis Patients , 2014, International journal of medical sciences.
[25] S. Juo,et al. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. , 2014, Journal of hepatology.
[26] P. Messa,et al. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? , 2012, Journal of viral hepatitis.
[27] U. Forssén,et al. The high comorbidity burden of the hepatitis C virus infected population in the United States , 2012, BMC Infectious Diseases.
[28] C. Sarrazin,et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[29] Ming‐Lung Yu,et al. Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based Study , 2010, The Kaohsiung journal of medical sciences.
[30] Yi-Wen Chiu,et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[31] I. Sheen,et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan , 2007, Alimentary pharmacology & therapeutics.
[32] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[33] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[34] Chien-Hung Chen,et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. , 2007, Journal of the Formosan Medical Association = Taiwan yi zhi.